Celldex Therapeutics (CLDX) Return on Capital Employed (2011 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Return on Capital Employed of 62.36% for Q1 2026, down 3276.0% year-over-year from 1.96% in Q1 2025, and down 22.54% quarter-over-quarter from 50.89% in Q4 2025.
Celldex Therapeutics (CLDX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Celldex Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 62.36% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3276.0% year-over-year to 62.36%; the TTM figure through Mar 2026 stood at 62.36% (down 3276.0% YoY), while the FY2025 annual figure was 45.14%, down 1204.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 62.36%, down from 50.89% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.55% in Q1 2022, with the low at 62.36% in Q1 2026.
- The 5-year median for Return on Capital Employed is 33.66% (2022), against an average of 35.13%.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed surged 2819 bps in 2024, then tumbled 3276 bps in 2026.
- Celldex Therapeutics' Return on Capital Employed stood at 33.66% in 2022, then sank by 34 bps to 45.21% in 2023, then soared by 44 bps to 25.39% in 2024, then slumped by 100 bps to 50.89% in 2025, then decreased by 23 bps to 62.36% in 2026.
- Business Quant data shows CLDX's Return on Capital Employed at 62.36% in Q1 2026, 50.89% in Q4 2025, and 41.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -55.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.65% |
| Mar 31, 2026 | -62.36% |
| Dec 31, 2025 | -50.89% |
| Sep 30, 2025 | -41.07% |
| Jun 30, 2025 | -34.37% |
| Mar 31, 2025 | -29.60% |
| Dec 31, 2024 | -25.39% |
| Sep 30, 2024 | -23.27% |
| Jun 30, 2024 | -21.19% |
| Mar 31, 2024 | -25.38% |
| Dec 31, 2023 | -45.21% |
| Sep 30, 2023 | -51.46% |
| Jun 30, 2023 | -40.93% |
| Mar 31, 2023 | -38.48% |
| Dec 31, 2022 | -33.66% |
| Sep 30, 2022 | -29.12% |
| Jun 30, 2022 | -26.29% |
| Mar 31, 2022 | -18.55% |
| Dec 31, 2021 | -16.34% |
| Sep 30, 2021 | -23.79% |